Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Harmful gut bacteria" is a **non-specific term** referring to any bacterial species within the gastrointestinal tract that can cause disease or disrupt normal physiological processes. These are also known as *pathogenic gut bacteria* or *intestinal pathogens*. Common examples include certain strains of *Clostridium perfringens*, *Staphylococcus* spp., and pathogenic strains of *Escherichia coli* (*E. coli*)[10]. These organisms can produce toxins, trigger inflammation, and lead to infections both locally in the gut and systemically if they translocate into the bloodstream[1][3]. The presence or overgrowth of harmful gut bacteria is associated with various diseases such as gastrointestinal infections, inflammatory bowel disease, sepsis, and may contribute to systemic conditions through immune activation or toxin release. Therapeutic strategies typically involve antibiotics targeted at the specific pathogen; however, indiscriminate use can lead to antibiotic resistance and disruption of beneficial commensal microbiota—resulting in dysbiosis with further health consequences[2][4]. Because "harmful gut bacteria" does not refer to a single molecular entity but rather a broad group defined by their negative impact on host health, it is not considered a canonical therapeutic target like an enzyme or receptor. Instead, interventions often aim at restoring microbial balance rather than targeting one specific molecule. **Note:** This entry is marked as incorrect for structured target databases because it lacks specificity—it refers collectively to many possible organisms rather than a unique molecular target.
Inhibition of bacterial cell wall synthesis (for beta-lactam antibiotics) Disruption of protein synthesis (for macrolides and tetracyclines) DNA replication inhibition (for fluoroquinolones)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Harmful gut bacterium.